Last week, HDN Investment Joint Stock Company, in collaboration with Relisys Medical Devices, successfully organized a specialized scientific workshop at 108 Military Central Hospital under the theme: "Latest Innovations in Transcatheter Aortic Valve Implantation (TAVI)”.

A Professional Scientific Forum Connecting Cardiovascular Experts

The event marked the opening activity of Relisys’ 2026 scientific workshop series, aiming to update advanced clinical knowledge, share real-world interventional experiences, and promote the application of advanced TAVI technologies in Vietnam’s cardiovascular intervention field. The workshop gathered numerous cardiologists, interventional specialists, and healthcare professionals currently working at 108 Military Central Hospital.

The presentation session fostered an open and engaging atmosphere for professional discussion during the workshop on “Latest Innovations in Transcatheter Aortic Valve Implantation (TAVI).”

The scientific forum created valuable opportunities for experts to exchange insights on the latest advancements in Transcatheter Aortic Valve Implantation (TAVI) techniques, clinical experience in patient selection and procedural applications, technological innovations enhancing treatment safety and effectiveness, future trends of TAVI amid aging populations, and increasing cardiovascular disease prevalence. Open discussions, in-depth clinical case analysis, and practical experience sharing brought meaningful value to participating physicians and specialists.
Explore: Explore Cardiovascular Medical Device Solutions from Relisys Medical Devices

Introducing the VIENNA Transcatheter Aortic Valve Solution from Relisys

During the workshop, Mr. Kanak Pandey, TAVI Clinical Specialist from Relisys Medical Devices, presented a specialized session on the VIENNA Transcatheter Aortic Valve System.

TAVI specialist Kanak Pandey continuously demonstrated and explained key procedural concepts using real product models during the scientific workshop.

The presentation highlighted several key advantages of the VIENNA valve compared to other products in the same category, along with its clinical applications in structural heart intervention. Key technological features presented included optimized valve design for improved deployment accuracy, advanced positioning control mechanisms during implantation, adaptability to diverse anatomical characteristics, potential to improve clinical outcomes, and reduce procedural complications.

The session attracted significant interest and generated extensive discussion among interventional cardiologists, reflecting growing attention toward advanced solutions for treating severe aortic valve disease.

About Us - HDN Investment Joint Stock Company

As the exclusive distributor of Relisys heart valves and coronary interventional devices in Vietnam, and as co-organizer of the workshop, HDN Investment Joint Stock Company continues to reaffirm its commitment to supporting healthcare institutions in accessing advanced cardiovascular technologies.

Representatives of HDN Investment Joint Stock Company, Relisys Medical Devices, together with cardiology experts and physicians from 108 Military Central Hospital, gathered for a commemorative photo during the scientific workshop.

HDN and Relisys remain dedicated to providing continuous professional training, supporting physician education and knowledge transfer, promoting advanced cardiovascular intervention technologies, and contributing to improved treatment quality and patient care. HDN sincerely appreciates the participation and active engagement of physicians and experts from 108 Military Central Hospital, whose contributions helped make the program a success.

In the coming period, HDN and Relisys will continue organizing nationwide scientific workshop series to create additional opportunities for academic exchange, practical experience sharing, and updates on innovative treatment solutions - contributing to the sustainable development of interventional cardiology in Vietnam.